{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:16:03Z","timestamp":1792419363688,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-024-01128-1","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T10:03:08Z","timestamp":1729591388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-2350","authenticated-orcid":false,"given":"Anna Lu\u00edza Soares","family":"de Oliveira Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-3022","authenticated-orcid":false,"given":"Jonathan N.","family":"Priantti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-2362","authenticated-orcid":false,"given":"Jhonny","family":"Limachi-Choque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"1128_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1101\/gad.348226.120","volume":"35","author":"J Li","year":"2021","unstructured":"Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35:787\u2013820.","journal-title":"Genes Dev"},{"key":"1128_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380.","journal-title":"Lancet"},{"key":"1128_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.gtc.2022.05.002","volume":"51","author":"RS Bresalier","year":"2022","unstructured":"Bresalier RS. Colorectal cancer screening in a changing world. Gastroenterol Clin North Am. 2022;51:577\u201391.","journal-title":"Gastroenterol Clin North Am"},{"key":"1128_CR4","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","volume":"22","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22:998\u20131009.","journal-title":"Curr Drug Targets"},{"key":"1128_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.crad.2021.09.003","volume":"76","author":"R Sinha","year":"2021","unstructured":"Sinha R. Colorectal cancer. Clin Radiol. 2021;76:870.","journal-title":"Clin Radiol"},{"key":"1128_CR6","first-page":"599","volume":"17","author":"WA Messersmith","year":"2019","unstructured":"Messersmith WA. NCCN guidelines updates: management of metastatic colorectal cancer. J Natl Compr Canc Netw. 2019;17:599\u2013601.","journal-title":"J Natl Compr Canc Netw"},{"key":"1128_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/bjs5.50299","volume":"4","author":"V V\u00e4yrynen","year":"2020","unstructured":"V\u00e4yrynen V, Wirta E-V, Sepp\u00e4l\u00e4 T, Sihvo E, Mecklin J-P, Vasala K, et al. Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study. BJS Open. 2020;4:685\u201392.","journal-title":"BJS Open"},{"key":"1128_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"1128_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372\u2013401.","journal-title":"CA Cancer J Clin"},{"key":"1128_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz H-J, K\u00f6hne C-H, Heinemann V, Tejpar S, Melez\u00ednek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"1128_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2023.101839","volume":"66","author":"L Klimeck","year":"2023","unstructured":"Klimeck L, Heisser T, Hoffmeister M, Brenner H. Colorectal cancer: a health and economic problem. Best Pract Res Clin Gastroenterol. 2023;66: 101839.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1128_CR12","first-page":"1","volume":"40","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Jakubowski CD, Fedewa SA, Davis A, Azad NS. Colorectal cancer in the young: epidemiology, prevention, management. Am Soc Clin Oncol Educ Book. 2020;40:1\u201314.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1128_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.critrevonc.2017.08.007","volume":"118","author":"MA Aziz","year":"2017","unstructured":"Aziz MA, Yousef Z, Saleh AM, Mohammad S, Al KB. Towards personalized medicine of colorectal cancer. Crit Rev Oncol Hematol. 2017;118:70\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1128_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s12885-024-12447-8","volume":"24","author":"FC Aquino de Moraes","year":"2024","unstructured":"Aquino de Moraes FC, Dantas Leite Pess\u00f4a FD, de Castro Duarte, Ribeiro CH, Rodrigues Fernandes M, Rodr\u00edguez Burbano RM, Carneiro Dos Santos NP. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2024;24:674.","journal-title":"BMC Cancer."},{"key":"1128_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1517\/13543781003593962","volume":"19","author":"MW Saif","year":"2010","unstructured":"Saif MW. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs. 2010;19:357\u201369.","journal-title":"Expert Opin Investig Drugs"},{"key":"1128_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/0008-5472.CAN-14-2240","volume":"75","author":"JF Linnekamp","year":"2015","unstructured":"Linnekamp JF, Wang X, Medema JP, Vermeulen L. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 2015;75:245\u20139.","journal-title":"Cancer Res"},{"key":"1128_CR17","doi-asserted-by":"publisher","first-page":"9667","DOI":"10.1038\/s41598-024-60449-0","volume":"14","author":"AAG Dantas","year":"2024","unstructured":"Dantas AAG, de Oliveira NPD, Costa GAB, Martins LFL, Dos Santos JEM, Migowski A, et al. Multilevel analysis of social determinants of advanced stage colorectal cancer diagnosis. Sci Rep. 2024;14:9667.","journal-title":"Sci Rep"},{"key":"1128_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","volume":"4","author":"S Misale","year":"2014","unstructured":"Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269\u201380.","journal-title":"Cancer Discov"},{"key":"1128_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.2174\/1389450121666200727121011","volume":"22","author":"D Sur","year":"2021","unstructured":"Sur D, Havasi A, Gorzo A, Burz C. A critical review of second-generation anti-EGFR monoclonal antibodies in metastatic colorectal cancer. Curr Drug Targets. 2021;22:1034\u201342.","journal-title":"Curr Drug Targets"},{"key":"1128_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","volume":"44","author":"AE Shin","year":"2023","unstructured":"Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44:222\u201336.","journal-title":"Trends Pharmacol Sci"},{"key":"1128_CR21","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/jso.27320","volume":"127","author":"BJ Kim","year":"2023","unstructured":"Kim BJ, Hanna MH. Colorectal cancer in young adults. J Surg Oncol. 2023;127:1247\u201351.","journal-title":"J Surg Oncol"},{"key":"1128_CR22","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3748\/wjg.v29.i10.1569","volume":"29","author":"W Leowattana","year":"2023","unstructured":"Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023;29:1569\u201388.","journal-title":"World J Gastroenterol"},{"key":"1128_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41568-021-00432-3","volume":"22","author":"H Ashktorab","year":"2022","unstructured":"Ashktorab H, Brim H. Colorectal cancer subtyping. Nat Rev Cancer. 2022;22:68\u20139.","journal-title":"Nat Rev Cancer"},{"key":"1128_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329:1271\u201382.","journal-title":"JAMA"},{"key":"1128_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/gastro\/goaa026","volume":"8","author":"Q-H Li","year":"2020","unstructured":"Li Q-H, Wang Y-Z, Tu J, Liu C-W, Yuan Y-J, Lin R, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf). 2020;8:179\u201391.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"1128_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.humpath.2018.07.028","volume":"82","author":"E-M Birkman","year":"2018","unstructured":"Birkman E-M, Avoranta T, \u00c5lgars A, Korkeila E, Lintunen M, Lahtinen L, et al. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. Hum Pathol. 2018;82:163\u201371.","journal-title":"Hum Pathol"},{"key":"1128_CR27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","volume":"9","author":"S Napolitano","year":"2024","unstructured":"Napolitano S, Martini G, Ciardiello D, Del Tufo S, Martinelli E, Troiani T, et al. Targeting the EGFR signalling pathway in metastatic colorectal cancer. Lancet Gastroenterol Hepatol. 2024;9:664\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1128_CR28","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.3390\/ijms21155311","volume":"21","author":"OO Ogunwobi","year":"2020","unstructured":"Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci. 2020;21:5311.","journal-title":"Int J Mol Sci"},{"key":"1128_CR29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/jnci\/djab069","volume":"113","author":"G Randon","year":"2021","unstructured":"Randon G, Yaeger R, Hechtman JF, Manca P, Fuc\u00e0 G, Walch H, et al. EGFR amplification in metastatic colorectal cancer. J Natl Cancer Inst. 2021;113:1561\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1128_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2217\/fon-2016-0468","volume":"13","author":"D Li","year":"2017","unstructured":"Li D, Fu Q, Li M, Li J, Yin C, Zhao J, et al. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis. Future Oncol. 2017;13:1115\u201327.","journal-title":"Future Oncol"},{"key":"1128_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-3-030-02771-1_8","volume":"1110","author":"M Martins","year":"2018","unstructured":"Martins M, Mansinho A, Cruz-Duarte R, Martins SL, Costa L. Anti-EGFR therapy to treat metastatic colorectal cancer: not for all. Adv Exp Med Biol. 2018;1110:113\u201331.","journal-title":"Adv Exp Med Biol"},{"key":"1128_CR32","doi-asserted-by":"publisher","first-page":"1048166","DOI":"10.3389\/fonc.2022.1048166","volume":"12","author":"B Doleschal","year":"2022","unstructured":"Doleschal B, Petzer A, Rumpold H. Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Front Oncol. 2022;12:1048166.","journal-title":"Front Oncol"},{"key":"1128_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1128_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1128_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1128_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1128_CR37","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.21873\/anticanres.15745","volume":"42","author":"H Tanioka","year":"2022","unstructured":"Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, et al. Phase II study of S-1 and irinotecan plus bevacizumab as second-line treatment for patients with metastatic colorectal cancer resistant to the fluoropyrimidine-oxaliplatin-cetuximab regimen. Anticancer Res. 2022;42:2675\u201381.","journal-title":"Anticancer Res"},{"key":"1128_CR38","doi-asserted-by":"publisher","unstructured":"Rossini D, Germani MM, Pagani F, Pellino A, Dell\u2019Aquila E, Bensi M, et al. Clin Colorectal Cancer. 2020;19:191\u2013199.e6. https:\/\/doi.org\/10.1016\/j.clcc.2020.03.009","DOI":"10.1016\/j.clcc.2020.03.009"},{"key":"1128_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852583","volume":"12","author":"S Mariani","year":"2022","unstructured":"Mariani S, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Donisi C, et al. Liquid biopsy-driven cetuximab rechallenge strategy in molecularly selected metastatic colorectal cancer patients. Front Oncol. 2022;12: 852583.","journal-title":"Front Oncol"},{"key":"1128_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/03008916221122554","volume":"109","author":"R D\u2019Onofrio","year":"2023","unstructured":"D\u2019Onofrio R, Caputo F, Prampolini F, Spallanzani A, Gelsomino F, Bettelli S, et al. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: evidence from clinical practice. Tumori. 2023;109:387\u201393.","journal-title":"Tumori"},{"key":"1128_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clcc.2021.07.001","volume":"20","author":"R Moretto","year":"2021","unstructured":"Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, et al. Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. Clin Colorectal Cancer. 2021;20:314\u20137.","journal-title":"Clin Colorectal Cancer"},{"key":"1128_CR42","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313\u20138.","journal-title":"Ann Oncol"},{"key":"1128_CR43","doi-asserted-by":"publisher","first-page":"9392","DOI":"10.1002\/cam4.5699","volume":"12","author":"G Martini","year":"2023","unstructured":"Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS\/BRAF wild-type circulating tumor DNA: individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Med. 2023;12:9392\u2013400.","journal-title":"Cancer Med"},{"key":"1128_CR44","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3390\/cancers15072117","volume":"15","author":"D Ciardiello","year":"2023","unstructured":"Ciardiello D, Napolitano S, Famiglietti V, Esposito L, De Falco V, Di Liello A, et al. Pretreatment plasma circulating tumor DNA RAS\/BRAF mutational status in refractory metastatic colorectal cancer patients who are candidates for anti-EGFR rechallenge therapy: a pooled analysis of the CAVE and VELO clinical trials. Cancers (Basel). 2023;15:2117.","journal-title":"Cancers (Basel)"},{"key":"1128_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-023-00963-9","volume":"18","author":"N Izawa","year":"2023","unstructured":"Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, et al. A phase II trial of trifluridine\/tipiracil in combination with cetuximab rechallenge in patients with RAS wild-type mCRC refractory to prior anti-EGFR antibodies: WJOG8916G trial. Target Oncol. 2023;18:369\u201381.","journal-title":"Target Oncol"},{"key":"1128_CR46","doi-asserted-by":"publisher","first-page":"1069370","DOI":"10.3389\/fonc.2023.1069370","volume":"13","author":"G Martini","year":"2023","unstructured":"Martini G, Ciardiello D, Napolitano S, Martinelli E, Troiani T, Latiano TP, et al. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS\/BRAF wild type tumors at start of first line: the CAPRI 2 GOIM trial. Front Oncol. 2023;13:1069370.","journal-title":"Front Oncol"},{"key":"1128_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3332\/ecancer.2020.1069","volume":"14","author":"A Karani","year":"2020","unstructured":"Karani A, Felismino TC, Diniz L, Macedo MP, Silva VSE, Mello CA. Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma?A retrospective analysis. Ecancermedicalscience. 2020;14:1069.","journal-title":"Ecancermedicalscience"},{"key":"1128_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940523","volume":"12","author":"S Napolitano","year":"2022","unstructured":"Napolitano S, Martini G, Ciardiello D, Di Maio M, Normanno N, Avallone A, et al. CAVE-2 (Cetuximab-AVElumab) mCRC: a phase II randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS\/BRAF wild-type mCRC patients. Front Oncol. 2022;12: 940523.","journal-title":"Front Oncol"},{"key":"1128_CR49","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1111\/ajco.13728","volume":"18","author":"CY Chong","year":"2022","unstructured":"Chong CY, Jalali A, Wong HL, Loft M, Wong R, Lee M, et al. Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. Asia Pac J Clin Oncol. 2022;18:e363\u20138.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1128_CR50","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/s12885-022-09892-8","volume":"22","author":"G Sommerh\u00e4user","year":"2022","unstructured":"Sommerh\u00e4user G, Kurreck A, Stintzing S, Heinemann V, von Weikersthal LF, Dechow T, et al. Study protocol of the FIRE-8 (AIO-KRK\/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine\/tipiracil plus panitumumab versus trifluridine\/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. BMC Cancer. 2022;22:820.","journal-title":"BMC Cancer"},{"key":"1128_CR51","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/oncolo\/oyac222","volume":"27","author":"JD Sorah","year":"2022","unstructured":"Sorah JD, Moore DT, Reilley MJ, Salem ME, Triglianos T, Sanoff HK, et al. Phase II single-arm study of palbociclib and cetuximab rechallenge in patients with KRAS\/NRAS\/BRAF wild-type colorectal cancer. Oncologist. 2022;27:1006\u2013e930.","journal-title":"Oncologist"},{"key":"1128_CR52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11523-021-00845-y","volume":"16","author":"A Tsuji","year":"2021","unstructured":"Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, et al. Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line panitumumab-based chemotherapy: JACCRO CC-09. Target Oncol. 2021;16:753\u201360.","journal-title":"Target Oncol"},{"key":"1128_CR53","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","volume":"7","author":"E Martinelli","year":"2021","unstructured":"Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7:1529\u201335.","journal-title":"JAMA Oncol"},{"key":"1128_CR54","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-015-1701-3","volume":"15","author":"X Liu","year":"2015","unstructured":"Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015;15:713.","journal-title":"BMC Cancer"},{"key":"1128_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000277635","volume":"33","author":"T Trarbach","year":"2010","unstructured":"Trarbach T, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, et al. Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I\/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologie. 2010;33:89\u201393.","journal-title":"Onkologie"},{"key":"1128_CR56","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/17425255.2021.1974397","volume":"17","author":"P Riera","year":"2021","unstructured":"Riera P, P\u00e1ez D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opin Drug Metab Toxicol. 2021;17:1157\u201363.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1128_CR57","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/nop2.1016","volume":"8","author":"S Sirilerttrakul","year":"2021","unstructured":"Sirilerttrakul S, Wannakansophon N, Utthiya P, Ckumdee S, Tangteerakoon P, Chansriwong P. Evaluation of adverse events and health-related quality of life in patients with colorectal cancer receiving ambulatory home-based chemotherapy in Thailand. Nurs Open. 2021;8:3036\u201344.","journal-title":"Nurs Open"},{"key":"1128_CR58","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jjco\/hyu008","volume":"44","author":"A Ooki","year":"2014","unstructured":"Ooki A, Ando M, Sakamoto J, Sato A, Fujii H, Yamaguchi K. A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. Jpn J Clin Oncol. 2014;44:383\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"1128_CR59","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1002\/cam4.1623","volume":"7","author":"S Iwamoto","year":"2018","unstructured":"Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, et al. A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial. Cancer Med. 2018;7:4217\u201327.","journal-title":"Cancer Med"},{"key":"1128_CR60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00384-024-04668-x","volume":"39","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Kelly FA, Souza MEC, Burbano RMR. Impact of adjuvant chemotherapy on survival after pathological complete response in rectal cancer: a meta-analysis of 31,558 patients. Int J Colorectal Dis. 2024;39:96.","journal-title":"Int J Colorectal Dis"},{"key":"1128_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22.","journal-title":"Signal Transduct Target Ther"},{"key":"1128_CR62","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","volume":"40","author":"J Zhou","year":"2021","unstructured":"Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40:328.","journal-title":"J Exp Clin Cancer Res"},{"key":"1128_CR63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.soc.2021.11.006","volume":"31","author":"S Sakata","year":"2022","unstructured":"Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31:255\u201364.","journal-title":"Surg Oncol Clin N Am"},{"key":"1128_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc.2016.126","volume":"17","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79\u201392.","journal-title":"Nat Rev Cancer"},{"key":"1128_CR65","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/oncolo\/oyad262","volume":"28","author":"PM Kasi","year":"2023","unstructured":"Kasi PM, Afable MG, Herting C, Lukanowski M, Jin Z. Anti-EGFR antibodies in the management of advanced colorectal cancer. Oncologist. 2023;28:1034\u201348.","journal-title":"Oncologist"},{"key":"1128_CR66","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMe0806778","volume":"359","author":"WA Messersmith","year":"2008","unstructured":"Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008;359:1834\u20136.","journal-title":"N Engl J Med"},{"key":"1128_CR67","first-page":"670","volume":"21","author":"J Gong","year":"2023","unstructured":"Gong J. EGFR inhibitor rechallenge in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2023;21:670\u20132.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1128_CR68","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.molonc.2014.05.003","volume":"8","author":"BO Van Emburgh","year":"2014","unstructured":"Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014;8:1084\u201394.","journal-title":"Mol Oncol"},{"key":"1128_CR69","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/cancers15153754","volume":"15","author":"JN Priantti","year":"2023","unstructured":"Priantti JN, Vilbert M, Madeira T, Moraes FCA, Hein ECK, Saeed A, et al. Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15:3754.","journal-title":"Cancers (Basel)"},{"key":"1128_CR70","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/14737140.2018.1502664","volume":"18","author":"TJ Price","year":"2018","unstructured":"Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, et al. Targeted therapy for metastatic colorectal cancer. Expert Rev Anticancer Ther. 2018;18:991\u20131006.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1128_CR71","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40265-018-0921-7","volume":"78","author":"C Gallois","year":"2018","unstructured":"Gallois C, Pernot S, Zaanan A, Taieb J. Colorectal cancer: why does side matter? Drugs. 2018;78:789\u201398.","journal-title":"Drugs"},{"key":"1128_CR72","doi-asserted-by":"publisher","first-page":"11645","DOI":"10.1007\/s13277-016-5140-9","volume":"37","author":"J Yang","year":"2016","unstructured":"Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, et al. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumour Biol. 2016;37:11645\u201355.","journal-title":"Tumour Biol"},{"key":"1128_CR73","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2019.09.001","volume":"143","author":"K Khan","year":"2019","unstructured":"Khan K, Valeri N, Dearman C, Rao S, Watkins D, Starling N, et al. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Crit Rev Oncol Hematol. 2019;143:153\u201363.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1128_CR74","doi-asserted-by":"publisher","unstructured":"Dienstmann R, Salazar R, Tabernero J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am Soc Clin Oncol Educ Book. 2015;e149\u2013156. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e149","DOI":"10.14694\/EdBook_AM.2015.35.e149"},{"key":"1128_CR75","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0065-2423(10)51004-7","volume":"51","author":"B Markman","year":"2010","unstructured":"Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem. 2010;51:71\u2013119.","journal-title":"Adv Clin Chem"},{"key":"1128_CR76","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757\u201370.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01128-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01128-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01128-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T10:08:32Z","timestamp":1729591712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01128-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01128-1","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"10 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. Furthermore, no patients or animals were involved in the design, conduct, or interpretation of our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9"}}